OncoMatch/Clinical Trials/NCT05902988
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Is NCT05902988 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies VLS-1488 for advanced solid tumor.
Treatment: VLS-1488 — This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Triple-Negative Breast Cancer
Breast Carcinoma
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Excluded: MSH2 deficient mismatch repair
dMMR
Excluded: POLE hotspot mutated
POLE gene hotspot mutated
Disease stage
Metastatic disease required
at least 1 site of measurable disease evaluable by CT scan or MRI per RECIST 1.1
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: kif18a inhibitor
Lab requirements
Cardiac function
mi or stroke ≤ 1 year, unstable angina/pe/dvt/cabg ≤ 6 months, nyha class ≥ ii, lvef < 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Southern California · Los Angeles, California
- Hoag Memorial Hospital · Newport Beach, California
- University of Colorado Cancer Center · Aurora, Colorado
- Yale Cancer Center · New Haven, Connecticut
- Kellogg Cancer Center · Evanston, Illinois
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05902988 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior kif18a inhibitor disqualifies patients from enrollment.
Are patients with MSH2 alterations eligible?
No. MSH2 deficient mismatch repair is an exclusion criterion.
Are patients with POLE alterations eligible?
No. POLE hotspot mutated is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify